BidaskClub cut shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a hold rating in a report published on Saturday.

Several other research analysts have also weighed in on SRPT. William Blair reissued an outperform rating on shares of Sarepta Therapeutics in a report on Monday, February 5th. Zacks Investment Research raised shares of Sarepta Therapeutics from a sell rating to a hold rating in a report on Wednesday. Barclays reissued a hold rating and set a $55.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, January 23rd. Janney Montgomery Scott began coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 3rd. They set a buy rating and a $75.00 price objective for the company. Finally, Needham & Company LLC reissued a buy rating on shares of Sarepta Therapeutics in a report on Friday, October 27th. One research analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have given a buy rating to the stock. Sarepta Therapeutics has a consensus rating of Buy and a consensus target price of $64.65.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at $55.14 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $68.90.

In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the transaction, the director now directly owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 9.60% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. American International Group Inc. boosted its stake in Sarepta Therapeutics by 3.8% during the 4th quarter. American International Group Inc. now owns 41,166 shares of the biotechnology company’s stock valued at $2,290,000 after purchasing an additional 1,522 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in Sarepta Therapeutics during the 4th quarter valued at about $217,000. Virtus Fund Advisers LLC boosted its stake in Sarepta Therapeutics by 547.9% during the 4th quarter. Virtus Fund Advisers LLC now owns 23,150 shares of the biotechnology company’s stock valued at $1,288,000 after purchasing an additional 19,577 shares during the period. BlackRock Inc. boosted its stake in Sarepta Therapeutics by 0.9% during the 4th quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock valued at $349,773,000 after purchasing an additional 58,433 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in Sarepta Therapeutics by 0.6% during the 4th quarter. Bank of New York Mellon Corp now owns 317,786 shares of the biotechnology company’s stock valued at $17,682,000 after purchasing an additional 1,983 shares during the period. 81.97% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://theolympiareport.com/2018/02/11/sarepta-therapeutics-srpt-rating-lowered-to-hold-at-bidaskclub.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.